PROCEDURAL BENEFIT OF SUBSTRATE BASE ABLATION VERSUS CONVENTIONAL MAPPING AND ABLATION OF CLINICAL STABLE VENTRICULAR TACHYCARDIA: RESULTS FROM THE VISTA RANDOMIZED TRIAL  by Biase, Luigi Di et al.
Arrhythmias and Clinical EP
A412
JACC March 17, 2015
Volume 65, Issue 10S
proCEdural bEnEfit of substratE basE ablation VErsus ConVEntional Mapping 
and ablation of CliniCal stablE VEntriCular taChyCardia: rEsults froM thE Vista 
randoMizEd trial
Poster Contributions
Poster Hall B1
Sunday, March 15, 2015, 3:45 p.m.-4:30 p.m.
Session Title: Arrhythmias and Clinical EP: VT
Abstract Category: 9. Arrhythmias and Clinical EP: VT
Presentation Number: 1218-237
Authors: Luigi Di Biase, John Burkhardt, Dhanunjaya Lakkireddy, Corrado Carbucicchio, Sanghamitra Mohanty, Chintan Trivedi, Prasant 
Mohanty, Pasquale Santangeli, Rong Bai, Giovanni Forleo, Rodney Horton, Shane Bailey, Javier Sanchez, Amin Al-Ahmad, Patrick 
Hranitzky, Gemma Pelargonio, Richard Hongo, Salwa Beheiry, Steven Hao, Madhu Reddy, Antonio Rossillo, Sakis Themistoclakis, Antonio 
Dello Russo, Claudio Tondo, Andrea Natale, Texas Cardiac Arrhythmia Institute, Austin, TX, USA
background:  Catheter ablation of ventricular tachycardia (VT) in patients with ischemic cardiomyopathy (IC) represents a valid therapeutic 
option versus AADs to reduce ICDs shocks and freedom from VT. We sought to evaluate whether a substrate based ablation approach 
produce procedural benefit when compared to conventional ablation of the clinical VT in a randomized prospective trial.
Methods:  This was an open-label, randomized, multicenter study. Patients were randomly assigned (1:1 ratio) to undergo ablation only 
of the presenting clinical VT at the site of the critical isthmus (group 1) versus a substrate-based ablation approach (group 2). Substrate 
ablation was empirically extended throughout the entire scar to target all “abnormal” electrograms. Procedural parameters were collected 
and analyzed.
results:  The final study population was composed by 118 pts (60 pts assigned to group 1, and 58 to group 2). The clinical baseline 
characteristics were not different between groups. The mean cycle length of the induced clinical VTs was 410±90 ms in group 1 and 
399±86 ms in group 2 (p=0.49). In group 2, pre ablation induction was not required by protocol and was performed in 22 patients. The 
procedural (4.6±1.6 and 4.2±1.3 hours [p= 0.14]) and fluoroscopy time (28±16 and 35±32 min, p=0.13) were not statistically different 
between groups. However, after removing group II patients where induction of VT was performed (22 cases), the procedural time 
decreased to 3.4±1.7 hr, which was significantly shorter than in group I [(4.2±1.3 vs. 3.4±1.7), p= 0.018]. Radiofrequency time was 
substantially longer in group 2 (35±27 and 68±21 minutes [p<0.001]). In addition, cardiopulmonary support for hemodynamic instability was 
used in 8 patients in group 1 and none in group 2 (p = 0.006).
Conclusion:  This is the first randomized trial showing that a substrate based approach allows ablation in sinus rhythm with a shorter 
procedural time and a lower likelihood to require hemodynamic support.
